Incidental lymphopenia and mortality: a prospective cohort study

Marie Warny MD, Jens Helby MD PhD, Børge Grønne Nordestgaard MD, Henrik Birgens MD, Stig Egil Bojesen MD

Cite as: CMAJ 2020 January 13;192:E25-33. doi: 10.1503/cmaj.191024

ABSTRACT

BACKGROUND: It is unknown if incidental lymphopenia detected in the general population is associated with higher all-cause and cause-specific mortality. We aimed to identify the associations between lymphopenia and all-cause and cause-specific mortality.

METHODS: In a prospective cohort study, we examined and followed participants enrolled in the Copenhagen General Population Study between November 2003 and April 2015. In our analysis, we modelled risks using Cox proportional hazards regression for 3 groups: participants with a lymphocyte count below the 2.5th percentile; those with a lymphocyte count at or between the 2.5th and 97.5th percentiles (reference category); and those with a lymphocyte count above the 97.5th percentile.

RESULTS: The cohort included 108 135 participants with a median age of 68 years. During a median follow-up of 9 (interquartile range [IQR] 0–14) years, 10 372 participants died. We found that participants with lymphopenia (lymphocyte count < 1.1 × 10^9/L) compared with those with a lymphocyte count in the reference range (1.1–3.7 × 10^9/L) had higher mortality with multivariable adjusted hazard ratios (HRs) of 1.63 (95% confidence interval [CI] 1.51–1.76) for all causes, 1.67 (95% CI 1.42–1.97) for nonhematologic cancers, 2.79 (95% CI 1.82–4.28) for hematologic cancers, 1.88 (95% CI 1.61–2.20) for cardiovascular diseases, 1.88 (95% CI 1.55–2.29) for respiratory diseases, 1.86 (95% CI 1.53–2.25) for infectious diseases, and 1.50 (95% CI 1.19–1.88) for other causes. For all-cause mortality, the highest absolute 2-year risks of death were observed in women (61%) and men (75%) who smoked and were aged 80 years or older with lymphocyte counts less than 0.5 × 10^9/L. Participants with a lymphocyte count higher than the reference category had increased mortality (adjusted HR 1.17, 95% CI 1.04–1.31).

INTERPRETATION: We found that lymphopenia was associated with an increased risk of all-cause and cause-specific mortality.

Lymphopenia in an otherwise healthy person is typically discovered when doing routine blood counts. In Denmark, patients with incidental lymphopenia are usually not referred for further examination because the mortality implications are unknown. In general, predictors of mortality are highly valued in everyday clinical practice because they help identify patients who may benefit from additional medical attention.

Observational studies have shown lymphopenia to be associated with risk of cardiovascular disease,1–5 cancer,5–11 liver disease (including alcohol abuse disorders)12,13 and systemic autoimmune disease.14–16 In a 2018 study involving 98 344 participants from the general population of Denmark, we found that lymphopenia was associated with a high risk of infectious disease.17 The risk of all-cause mortality for patients with incidental lymphopenia is not known. This study aimed to identify the associations between lymphopenia and all-cause and cause-specific mortality.

Methods

We followed the reporting standards outlined in the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.18

Study design and participants

Participants who were white, of Danish descent and aged 20–100 years were eligible if they participated in the Copenhagen General Population Study.17 a prospective cohort study that enrolled participants from November 2003 to April 2015 from suburbs in and around Copenhagen, Denmark.19–21 Further details can be found in Appendix 1, Supplementary Methods,
available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.191024/-/DC1. We enrolled participants using the Danish Civil Registration System,²² they answered a questionnaire about health and lifestyle (Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.191024/-/DC1), and each participant underwent a physical examination (Appendix 3, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.191024/-/DC1) during which blood samples were drawn. All participants gave written, informed consent.

Blood samples were drawn on the day that participants were examined and white blood cell counts were measured immediately using the ADVIA 120 Hematology system. Precision of the measurements was monitored daily: day-to-day coefficient of variation was typically 2%–5% (in the range of 1.5–1.7 × 10⁹/L lymphocytes). We notified participants and recommended further medical evaluation if their blood sample had a total leukocyte count above 50 × 10⁹/L (indication of a high risk of leukemia).

We used the Danish Civil Registration System to access dates of death for all participants who died before Apr. 19, 2018. The register holds information on all individuals alive and living in Denmark and is continuously updated with vital statistics data.²³ We defined all-cause mortality as death regardless of cause, which was further classified according to the cause of death using the Danish Register of Causes of Death.²² Using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10), deaths were classified as non-hematologic cancer mortality, hematologic cancer mortality, cardiovascular mortality, respiratory mortality and infectious disease mortality (Appendix 1, Supplementary Table S1). The remaining causes of death were classified as other mortality. In Denmark, physicians may list several causes of death on the death certificate. Therefore, some individuals had causes of death in more than 1 category. Information on cause of death was available until Dec. 31, 2015, because this was the latest update available on causes of death.

Covariates

We chose covariates a priori based on a 2014 WHO report evaluating the most common risk factors for all-cause mortality.²⁴ We also included covariates associated with lymphopenia.¹³,²⁵⁻²⁷ Specific information on covariates associated with lymphopenia can be found in Appendix 1, Supplementary Methods. Missing values (0.9% on average; Appendix 1, Supplementary Table S2) were imputed.

Statistical analysis

We conducted the statistical analysis using Stata version 13.1. All statistical tests were 2-sided. Differences in baseline characteristics were assessed using Cuzick’s extension to the Wilcoxon rank sum test for continuous variables or logistic regression for categorical variables.

We modelled risks of all-cause and cause-specific mortality separately using Cox proportional hazards regression, with lymphocyte counts categorized into the following 3 groups: participants were considered to have lymphopenia if their lymphocyte count was below the 2.5th percentile; a reference category was created with a lymphocyte count at or between the 2.5th and 97.5th percentiles; and participants were considered to have lymphocytosis if their lymphocyte count was above the 97.5th percentile. We used restricted cubic splines²⁸ for presentation of results from the Cox models. When we analyzed all-cause mortality, we considered follow-up to begin at the date of examination and end on the date of death due to any cause, emigration or Apr. 19, 2018, whichever came first. When we analyzed cause-specific mortality, we considered follow-up to end on the date of cause-specific death, emigration or Dec. 31, 2015, whichever came first. We accounted for competing risk of death in analyses of cause-specific mortality by calculating subhazard ratios using Fine and Gray’s method.²⁹

We plotted cumulative mortality using a multivariable-adjusted Fine and Gray regression model of all-cause mortality, taking emigration as a competing event into consideration. This method allows calculation of cumulative incidence not influenced by emigration. We tested for interactions by using likelihood ratios.

We used age as the underlying time scale (= age adjusted) in the Cox and Fine and Gray models, and the multivariable models were additionally adjusted for birth year, sex, smoking status, cumulative smoking in pack-years, alcohol consumption, body mass index, plasma C-reactive protein, blood neutrophil count, recent infections, diabetes, systolic blood pressure, plasma cholesterol, plasma triglycerides, education, income and leisure-time physical activity.

Appendix 1 (Supplementary Methods) contains information on how we handled missing data. We also adjusted the main analyses for regression dilution bias because this reduces the influence of biological and measurement variability of lymphocyte count on risk estimates. We calculated regression toward the mean³⁰ by using repeat measurements of lymphocyte counts in 5181 participants after a median of 10.5 (interquartile range [IQR] 9.9–10.8) years. We based the ratio on the median result value in the groups with lymphopenia and lymphocytosis, using the 2.5th and 97.5th percentile cut-offs for lymphocyte counts at the first date of examination (calculated as 0.68).

Because lymphocyte count declines with increasing age³¹,³² (Appendix 1, Supplementary Figure S3), we redefined lymphopenia by calculating the age-adjusted 2.5th percentile for lymphocyte count for each 10-year age group.

Subclinical, but undiagnosed disease, present on the day of examination could affect both lymphocyte count and mortality. Therefore, we subdivided follow-up time into 3 time intervals of 0–4, 4–8 and more than 8 years, to assess if follow-up time affected the association between lymphopenia and all-cause mortality. We excluded all individuals with either diagnosed comorbidity, as defined by the Charlson Comorbidity Index, or with results that deviated from reference values for routine blood tests (Appendix 1, Supplementary Methods). When comparing risk estimates, we used the Z-test described by Bland and Altman.³³ In addition, we adjusted the main analysis of all-cause mortality for the Charlson Comorbidity Index. We created a prediction algorithm to show participants’ absolute 2-year risk of
all-cause mortality using the Framingham Risk Score as inspiration\(^3\) (Appendix 1, Supplementary Figure S11).

**Ethics approval**
This study was approved by a Danish ethical committee (H-KF-01–144/01).

**Results**

Table 1 presents baseline characteristics of 108,136 included participants from the Copenhagen General Population Study according to blood lymphocyte count; we present absolute differences between the 3 groups. Lymphocyte concentrations ranged from 0.1 to 125 \(\times 10^9\)/L and were almost normally distributed (Appendix 1, Supplementary Figure S4). A total of 61 people who were not white and not of Danish descent were excluded. No participants were lost to follow-up, and 456 emigrated and were excluded. Missing values were imputed; however, results were similar without imputation. Complete population characteristics, numbers of missing information and explanations for missing values can be found in Appendix 1, Supplementary Table S2. During a median follow-up of 9 (IQR 0–14) years, 10,372 participants died before Apr. 19, 2018. A flowchart of participants is available (Appendix 1, Supplementary Figure 2).

After we adjusted for age and sex, the hazard ratio (HR) for all-cause mortality was 1.63 (95% confidence interval [CI] 1.51–1.76) in participants with lymphopenia and 1.47 (95% CI 1.31–1.65) in participants with lymphocytosis when compared with participants with lymphocytes in the reference range (Figure 1). In the multivariable-adjusted model, we determined that the corresponding HRs were 1.63 (95% CI 1.51–1.76) and 1.17 (95% CI 1.04–1.31), respectively. After adjustment for regression dilution bias the corresponding HRs were also significant (Appendix 1, Supplementary Figure S5).

Figure 2 presents the cumulative mortality in participants with lymphopenia (lymphocyte count < 1.1 \(\times 10^9\)/L) versus those

| Characteristic | Participants with lymphopenia (lymphocyte count < 1.1 \(\times 10^9\)/L) | Reference group (lymphocyte count = 1.1–3.7 \(\times 10^9\)/L) | Participants with lymphocytosis (lymphocyte count > 3.7 \(\times 10^9\)/L) |
|---------------|-------------------------------------------------|--------------------------------------------------|--------------------------|
|                | No. (%) of participants*                          | No. (%) of participants*                           | No. (%) of participants* |
| Blood lymphocyte count, \(\times 10^9\)/L; median (IQR) | 1.0 (0.1–1.09) | 2.1 (1.1–3.69) | 4.0 (3.7–125) |
| Age, yr; median (IQR) | 68 (58–77) | 58 (48–67) | 58 (48–66) |
| Male sex | 1465 (55) | 46145 (45) | 986 (38) |
| Ever smoked | 1529 (58) | 59102 (57) | 1951 (75) |
| Cumulative smoking, pack-years; \(\dagger\) median (IQR) | 16 (5–32) | 15 (6–30) | 25 (13–40) |
| Alcohol consumption > 168 g/wk for men, > 84 g/wk for women\(\ddagger\) | 1081 (41) | 40261 (39) | 938 (36) |
| Body mass index, kg/m\(^2\); median (IQR) | 25 (23–28) | 26 (23–28) | 27 (24–30) |
| Plasma C-reactive protein, mg/L; median (IQR) | 1.6 (1.0–3.4) | 1.4 (0.9–2.2) | 1.8 (1.2–3.4) |
| Blood neutrophil count, \(\times 10^9\)/L; median (IQR) | 3.7 (2.9–4.8) | 4.0 (3.3–4.9) | 5.0 (4.1–6.1) |
| Any recent infection | 136 (5) | 3969 (4) | 139 (5) |
| Diabetes | 164 (6) | 3717 (4) | 125 (5) |
| Systolic blood pressure, mm Hg; median (IQR) | 142 (128–158) | 140 (126–155) | 141 (128–158) |
| Plasma cholesterol, mmol/L; median (IQR) | 5.3 (4.5–6.0) | 5.5 (4.8–6.3) | 5.8 (5.1–6.5) |
| Plasma triglycerides, mmol/L; median (IQR) | 1.2 (0.9–1.8) | 1.4 (0.9–2.0) | 1.8 (1.2–2.7) |
| High income\(\S\) | 1288 (49) | 65389 (64) | 1499 (57) |
| High leisure-time physical activity\(\P\) | 1257 (48) | 53066 (52) | 1053 (40) |
| More than 12 years of education | 2063 (78) | 81322 (79) | 1842 (71) |
| Comorbidity** | 2095 (79) | 55635 (54) | 1819 (70) |

Note: IQR = interquartile range.
*Unless specified otherwise.
\(\dagger\)Only ever smokers.
\(\ddagger\)Values from The Danish State Health Authority (latest national recommendations available at www.sst.dk/da/Udgivelser/2018/Forebyggelsespakke-Alkohol [in Danish]).
\(\S\)Greater than or equal to 400,000 Danish krone/household.
\(\P\)More than 4 hours of physical activity a week.
**Defined as participants with any comorbidity or with routine blood test results outside the reference range.
with a lymphocyte count in the reference range \((1.1–3.7 \times 10^9/L)\) (log-rank < 0.001).

We found that the risk estimates for all-cause mortality in participants with lymphopenia compared with those with lymphocyte counts in the reference range were more pronounced in participants at or below age 70 years than in those above age 70 years \((p\) for interaction < 0.001) (Figure 3). This was true regardless of whether lymphopenia was defined as participants having a lymphocyte count of less than \(1.1 \times 10^9/L\), the 2.5th percentile for the entire population or whether the cut-off was defined separately for each 10-year age group (Figure 3 and Appendix 1, Supplementary Figure S6).

In analyses of mortality, stratified for the covariates associated with lymphopenia at baseline (Appendix 1, Supplementary Figure S7), we found a significant interaction between lymphocyte count and age \((p < 0.001)\), and lymphocyte count and leisure time physical activity \((p = 0.004)\); these significant \(p\) values indicate that risk of all-cause mortality by lymphopenia was lower in those participants older than 70 years of age compared with those aged 70 years or younger and in those with leisure time physical activity of less than 4 hours versus those with 4 or more hours per week.

A total of 7029 participants died before Dec. 31, 2015 (non-hematologic cancers, \(n = 2663\); hematologic cancers, \(n = 218\); cardiovascular diseases, \(n = 2005\); respiratory diseases, \(n = 1342\); infectious diseases, \(n = 1299\); and other causes, \(n = 1207\)) during a median follow-up of 7 (IQR 0–12) years.

In multivariable-adjusted models, we found that participants with lymphopenia had higher mortality than those with lymphocyte counts in the reference range for all causes of mortality: HR for nonhematologic cancers 1.67 (95% CI 1.42–1.97), HR for hematologic cancers 2.79 (95% CI 1.82–4.28), HR for cardiovascular diseases 1.88 (95% CI 1.61–2.20), HR for respiratory diseases 1.88 (95% CI 1.55–2.29), HR for infectious diseases 1.86 (95% CI 1.53–2.25) and HR for other causes 1.50 (95% CI 1.19–1.88) (Figure 4).

Figure 1: All-cause mortality as a function of lymphocyte count in participants from the Copenhagen General Population Study.17 Solid red lines are HRs and broken black lines indicate 95% CIs based on fitting of cubic splines to risk estimates obtained using Cox Proportional Hazards regression. We used age as the underlying time scale; we also adjusted the multivariable adjusted model for birth year, sex, smoking status, cumulative smoking in-pack-years, alcohol consumption, body mass index, level of plasma C-reactive protein, blood neutrophil count, recent infections, diabetes, systolic blood pressure, level of plasma cholesterol, level of plasma triglycerides, education, income and leisure-time physical activity. We set the median lymphocyte value \((2.1 \times 10^9/L)\) as the reference for the continuous model. When categorizing lymphocyte counts, we considered lymphopenia to be present when a participant had a lymphocyte count lower than \(1.1 \times 10^9/L\) (2.5th percentile); the reference category was lymphocyte count between 1.1 and \(3.7 \times 10^9/L\) (2.5th to 97.5th percentile). We considered lymphocytosis to be present when a participant had a lymphocyte count above \(3.7 \times 10^9/L\) (97.5th percentile). Note: Estimates for all-cause mortality in individuals with lymphopenia are identical in the 2 models. CI = confidence interval, HR = hazard ratio.

We determined that redefining lymphopenia using different cut-off values produced mortality estimates that were similar to our main findings (Appendix 1, Supplementary Figure S8). When we subdivided follow-up time (Figure 5), the multivariable adjusted HR for mortality more than 8 years after the day of examination was 1.50 (95% CI 1.27–1.77). To further exclude undiagnosed comorbidity as the explanation for our results, we excluded all participants with either diagnosed comorbidity or with results from routine blood tests that deviated from reference values on the day of examination \((n = 48 567)\) (Appendix 1, Supplementary Figure S9). The risk estimates were similar to those obtained when evaluating all participants \((p\) value for difference = 0.20). We obtained similar results for all-cause mortality after adjusting the main analysis with the Charlson Comorbidity Index (Appendix 1, Supplementary Figure S10).

Our prediction algorithm found the combination of lymphopenia with other risk factors categorized participants in groups...
Age, yr
Individuals, no.
Deaths, no.
Deaths/100 000 person years
Cut-off for lymphopenia, x 10⁹/L,
2.5th percentile in the study population
HR
(95% CI)
≤ 50 > 50–60 > 60–70 > 70–80 > 80
31 374 26 418 27 499 15 395 4840
≤ 50 > 50–60 > 60–70 > 70–80 > 80
3.45 2.87 2.42 1.46 1.43
(1.27–5.22) (2.03–4.06) (2.04–2.87) (1.29–1.67) (1.26–1.63)

Figure 3: All-cause mortality as a function of lymphopenia stratified by age for participants from the Copenhagen General Population Study. We used age as the underlying time scale and additionally adjusted the multivariable model for birth year, sex, smoking status, cumulative smoking in pack-years, alcohol consumption, body mass index, level of plasma C-reactive protein, blood neutrophil count, recent infections, diabetes, systolic blood pressure, level of plasma cholesterol, level of plasma triglycerides, education, income and leisure-time physical activity. Participants were categorized in 10-year age groups, and we considered those with a lymphocyte count lower than 1.1 x 10⁹/L to have lymphopenia. Note: p value for interaction was calculated according to a likelihood ratio test. CI = confidence interval, HR = hazard ratio.
Figure 4: Cause-specific mortality as a function of lymphocyte count for participants from the Copenhagen General Population Study. Solid red lines are multivariable adjusted HRs and broken black lines indicate 95% CIs based on fitting of cubic splines to risk estimates obtained using Cox Proportional Hazards regression. We obtained subhazard ratios using a Fine and Gray regression. Age was used as the underlying time scale and we additionally adjusted the multivariable model by birth year, sex, smoking status, cumulative smoking in pack-years, alcohol consumption, body mass index, level of plasma C-reactive protein, blood neutrophil count, recent infections, diabetes, systolic blood pressure, level of plasma cholesterol, level of plasma triglycerides, education, income and leisure-time physical activity. We set the median lymphocyte value (2.1 x 10^9/L) as the reference for the continuous model. The sum of cause-specific deaths exceeds the total number of deaths because participants may have had several causes of death listed on their death certificate. Note: CI = confidence interval, HR = hazard ratio, Ref. = reference category.
interpretation

In this prospective cohort study involving participants from the general population in Denmark, we found that lymphopenia (lymphocyte count < 1.1 × 10^9/L) with those who had a lymphocyte count in the reference range (1.1–3.7 × 10^9/L). We used age as the underlying time scale and additionally adjusted the multivariable model by birth year, sex, smoking status, cumulative smoking in pack-years, alcohol consumption, body mass index, level of plasma C-reactive protein, blood neutrophil count, recent infections, diabetes, systolic blood pressure, level of plasma cholesterol, level of plasma triglycerides, education, income and leisure-time physical activity. We subdivided follow-up time into 3 time intervals, and we included participants in more than 1 time interval if total follow-up was more than 4 years. Note: p for interaction was calculated according to a likelihood ratio test. CI = confidence interval, HR = hazard ratio.

with absolute 2-year risks of all-cause mortality from below 1% to the highest in women (61%) and men (75%) who smoked and were aged 80 years or older with lymphocyte counts less than 0.5 × 10^9/L.

Figure 5: All-cause mortality stratified by follow-up interval for participants from the Copenhagen General Population Study.\(^\text{17}\) We compared participants with lymphopenia (lymphocyte count < 1.1 × 10^9/L) with those who had a lymphocyte count in the reference range (1.1–3.7 × 10^9/L). We used age as the underlying time scale and additionally adjusted the multivariable model by birth year, sex, smoking status, cumulative smoking in pack-years, alcohol consumption, body mass index, level of plasma C-reactive protein, blood neutrophil count, recent infections, diabetes, systolic blood pressure, level of plasma cholesterol, level of plasma triglycerides, education, income and leisure-time physical activity. We subdivided follow-up time into 3 time intervals, and we included participants in more than 1 time interval if total follow-up was more than 4 years. Note: p for interaction was calculated according to a likelihood ratio test. CI = confidence interval, HR = hazard ratio.
and short progression-free survival in patients with breast cancer, sarcomas and non-Hodgkin lymphoma. To illustrate the predictive capacity of the lymphocyte count, we determined absolute 2-year risks of all-cause mortality in participants from a general population. We found that risk estimates were highly affected by the lymphocyte count, indicating that a selected group (e.g., smokers older than 80 years with a low lymphocyte count) might benefit from additional surveillance, although there is no evidence that this will decrease mortality.

Limitations
We could not clarify questions of causality. Participants may have had subclinical and potentially fatal disease on the day of examination, which might have affected their lymphocyte count and mortality risk. However, since the association between lymphopenia and high mortality remained for several years after participants were examined, this is unlikely to have biased our findings. Nonetheless, some of the observed association may be explained by residual confounding. Iatrogenic causes of lymphopenia such as medication and blood donations could not be evaluated because data were not available. A limitation to the analyses of cause-specific mortality was the potential misclassification of causes, because we obtained the data directly from the national Danish Register of Causes of Death without adjudication. However, misclassification of cause of death would be biased toward the null hypothesis because the attending physician is not likely to have known the lymphocyte count measured in this research cohort. In population-based studies, participants with comorbidities are less likely to participate, which generates a healthy participant bias, but this is more likely to bias our results toward the null hypothesis and probably does not explain our observed association between lymphopenia and high mortality. Lastly, the generalizability of the results may be limited because our study involved only participants who were white and of Danish descent. It remains to be seen if lymphopenia increases risk of mortality in nonwhite populations.

Conclusion
In this prospective cohort study, we found that incidental lymphopenia was associated with a 1.6-fold increase in risk of all-cause mortality and a 1.5 to 2.8-fold increased risk of cause-specific mortality. Using the absolute 2-year risks of all-cause mortality, prognostic value of baseline lymphocyte count in cervical carcinoma treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2008;71:199-204.

16. Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006;32:22-8.

17. Ray-Coquard I, Crozet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009;69:5383-91.

18. Owney HE, Roi LD, Isenberg RR, et al. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 1983; 52:126-30.

19. De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 2012;12:264-9.

20. Saroja S, Uzzo RG, Plimack ER, et al. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol 2013;189:454-61.

21. Matsos LC, Batista P, Monteiro N, et al. Lymphocyte subsets in alcoholic liver disease. World J Hepatol 2013;5:46-55.

22. Zuluaga P, Sanvisens A, Teniente A, et al. Wide array of T-cell subpopulation alterations in patients with alcohol use disorders. Drug Alcohol Depend 2016;162:124-9.

23. Greer JP, Foerster J, Rodgers GM, et al. Wintrobe’s clinical hematology, volume 2. 12th edition. Philadelphia (PA): Lippincott Williams & Wilkins; 2009:1514.

24. Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978;21:295-305.

25. Hepburn AE, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 2010;49:2243-54.

26. Wamy M, Helby J, Nordestgaard BG, et al. Lymphopenia and risk of infection and infection-related death in 98 344 individuals from a prospective Danish population-based study. PLoS Med 2018;15:e1002685.

27. von Elm E, Altman DG, Egger M, et al. The Strengthening of the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. J Clin Epidemiol 2006;61:344-9.

28. Rode L, Nordestgaard BG, Bojesen SE. Peripherale blood lymphocyte telomere length and mortality among 64 637 individuals from the general population. J Natl Cancer Inst 2015;107:dju74.

29. Afzal S, Tybjærg-Hansen A, Jensen GB, et al. Change in body mass index associated with lowest mortality in Denmark, 1976-2013. JAMA 2016;315:1989-96.

30. Lehtonen L, Eskola J, Vainio O, et al. Changes in lymphocyte subsets and telomere length and mortality among 64 637 individuals from the general population. Haematologica 2017;102:1457-65.

31. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39(Suppl 7):26-9.

32. Pedersen CB, Gøtzsche H, Møller JØ, et al. The Danish civil registration system. A cohort of eight million persons. Dan Med Bull 2006;53:441-9.

33. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014. Available: www.who.int/nmh/publications/ncd-status-report-2014/en/ (accessed 2018 Oct. 11).

34. Givi ME, Folkerts G, Wagenaar GTM, et al. Cigarette smoke differentially modulates dendritic cell maturation and function in time. Respir Res 2015;16:131.

35. Falkow S, Vogt T, Widdowson E. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 2016;60:43-57.

36. Durrieusen S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-61.

37. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.

38. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-53.

39. Lehtonen L, Eskola J, Vainio O, et al. Changes in lymphocyte subsets and telomere length and mortality in cervical carcinoma treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys 1999;52:126-30.

40. De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 2012;12:264-9.

41. Acohido AF, Mooney MA, Regalado S, et al. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 1983; 52:126-30.

42. De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 2012;12:264-9.

43. Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. J Immunol 2011;186:5541-8.

44. Givi ME, Folkerts G, Wagenaar GTM, et al. Cigarette smoke differentially modulates dendritic cell maturation and function in time. Respir Res 2015;16:131.
35. Rea IM, Stewart M, Campbell P, et al. Changes in lymphocyte subsets, interleukin 2, and soluble interleukin 2 receptor in old and very old age. Gerontology 1996;42:69-78.
36. Nikolich-Zugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol 2008;8:512-22.
37. Qin L, Jing X, Qiu Z, et al. Aging of immune system: immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging (Albany NY) 2016;8:948-59.
38. Franceschi C, Valensin S, Fagnoni F, et al. Biomarkers of immunosenescence within an evolutionary perspective: the challenge of heterogeneity and the role of antigenic load. Exp Gerontol 1999;34:911-21.
39. Vasto S, Candore G, Balistreri CR, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 2007;128:83-91.
40. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004;5:133-9.
41. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 1996;49:646-6.
42. Tollerud DJ, Clark JW, Brown LM, et al. The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers. J Clin Immunol 1989;9:214-22.

**Competing interests:** None declared.

This article has been peer reviewed.

**Affiliations:** Departments of Hematology (Warny, Birgens), Internal Medicine (Helby) and Clinical Biochemistry (Helby, Nordestgaard, Bojesen), Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; Faculty of Health and Medical Science (Warny, Nordestgaard, Birgens, Bojesen), University of Copenhagen, Copenhagen, Denmark

**Contributors:** All of the authors directly participated in the planning, execution and analyses of the study; critically revised the manuscript for important intellectual content; gave final approval of the version to be published; and agreed to be accountable for all aspects of the work.

**Funding:** This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 667837. The funders had no role in this study.

**Data sharing:** The Copenhagen General Population Study (CGPS) cannot share individual participant data owing to the Danish Data Protection Act on protection of personal data. We are, however, very keen to collaborate whenever possible, and the steering committee of the CGPS can be contacted through emails to Børge Grønne Nordestgaard or Stig Egil Bojesen. Depending on the collaboration, the steering committee and the collaborator will then determine the exact volume and form of data.

**Accepted:** Nov. 20, 2019

**Correspondence to:** Stig Egil Bojesen, stig.egil.bojesen@regionh.dk